In complex neurological diseases, such as multiple sclerosis, stroke or spinal cord injuries, a treatment with stem cells may be the sole remaining choice of cure

Find out more


The World’s Lightest and Smartest “Wear-and-Forget” Companion Device for Ambient Assisted Living

Find out more


To provide innovation in high-tech fields/high-growth sectors requiring multi-disciplinary approaches and know-how.
from bio-electronics, smart sensors and systems to advanced solutions for nano-medicine, cell-therapies, and drug delivery.


Our vision is to innovate within both the health care and medical fields by repositioning state of the art technologies in order to improve people’s quality of life and cost of care.


We provide research & development expertise and hands-on experience to support feasibility studies and business innovation.

We work with an experienced team of designers and expert engineers, medical advisors, biologists, material scientists and project managers, allocated as technical staff to each project. This allows an effective and sustainable way to achieve the project goals timely and with the right focus.

We work with third parties in a foundry-based manufacturing scheme to scale-up the products into the global market.

View More



CITC Ltd awarded with an Innovate UK Health and Life Sciences competition grant to investigate the potential of novel chemotherapies in its humaNase project

Cambridge, 2nd August 2018 - Innovate UK, the UK’s innovation agency has awarded CITC Ltd funding for their humaNase project.

A powerful therapeutic strategy against some cancers, notably Acute Lymphoblastic Leukaemia (ALL), has been to starve the cells of ASN by utilizing the enzyme L-asparaginase (ASNase) which converts ASN to aspartate which cannot be used by cancerous cells. The ASNase enzymes currently employed clinically are derived from bacteria, meaning they frequently invoke allergic reactions in patients, and they can give rise to toxic side effects due to unwanted glutaminase (GLS) activity of the ASNase.

Read More

CITC partners in the new B2B European consortium to develop the first 3D organ-on-chip device modelling Breast Cancer

Cambridge, 30th July 2018 - The European project B2B aims at Modelling spontaneous Breast cancer metastasis to the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

1 in 8 women are affected by Breast Cancer, and it’s most common metastatic site is the bone. The mechanism by which these breast cancer cells spread to the bone is still largely unknown, this lack of understanding is a major stumbling block to overcoming breast cancer mortality. Up to date, there have been no metastasis-suppressing agents found.

The aim of the device would be to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context.

Read More

CITC Ltd partner with Zinergy at IDTechEx conference to introduce its new Patch4Life™ platform to the public for the first time.

Berlin - Germany, 12th April 2018 - The IDTechEx Conference (emerging technologies unleashed) in Berlin yesterday, saw CEO of Zinergy, Dr Pritesh Hiralal discuss the future of printed, flexible energy storage and its application in healthcare patches with specific reference to CITC’s Patch4life™ and the technology used within.
Read More

Personalised stem cell treatment to provide relief to people with progressive MS

Cambridge, 22nd February 2017 - Scientists within the Department of Clinical Neurosciences at Cambridge University with close links with CITC Ltd. have demonstrated the ability to directly re-programme skin cells into brain stem cells that when transplanted into the central nervous system help reduce inflammation and may help repair the damaged tissue caused by multiple sclerosis.

Read More

© Copyright 2019 Cambridge Innovation Technologies Consulting LtdWeb Design By Toolkit Websites